Research Analysts Offer Predictions for AKRO Q3 Earnings

Key Points

• HC Wainwright expects Akero Therapeutics (NASDAQ:AKRO) to report Q3 2025 earnings of ($0.90) per share, maintaining a "Buy" rating with a target price of $72.00.
• Eight analysts currently hold a consensus rating of "Buy" for the stock, with an average price target of $81.14.
• Insider selling has been significant, with $10.1 million worth of shares sold over the last three months, representing a decrease in ownership for key insiders.

Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) - Investment analysts at HC Wainwright issued their Q3 2025 earnings per share estimates for shares of Akero Therapeutics in a report released on Thursday, September 4th. HC Wainwright analyst A. Fein forecasts that the company will post earnings of ($0.90) per share for the quarter. HC Wainwright currently has a "Buy" rating and a $72.00 price target on the stock. The consensus estimate for Akero Therapeutics' current full-year earnings is ($3.99) per share. HC Wainwright also issued estimates for Akero Therapeutics' Q4 2025 earnings at ($0.94) EPS, FY2025 earnings at ($3.61) EPS, FY2026 earnings at ($4.01) EPS, FY2027 earnings at ($4.73) EPS, FY2028 earnings at ($3.34) EPS and FY2029 earnings at ($1.65) EPS.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last released its quarterly earnings results on Friday, August 8th. The company reported ($0.86) EPS for the quarter, topping analysts' consensus estimates of ($0.97) by $0.11. During the same period in the prior year, the business earned ($0.81) EPS.

Several other brokerages have also recently weighed in on AKRO. TD Cowen assumed coverage on Akero Therapeutics in a report on Monday, August 4th. They issued a "buy" rating and a $76.00 price objective for the company. Cowen initiated coverage on Akero Therapeutics in a report on Monday, August 4th. They issued a "buy" rating for the company. Bank of America lifted their price target on Akero Therapeutics from $63.00 to $64.00 and gave the stock a "buy" rating in a report on Tuesday, May 27th. Finally, Wall Street Zen upgraded Akero Therapeutics from a "sell" rating to a "hold" rating in a report on Saturday, August 16th. Eight analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the stock presently has an average rating of "Buy" and an average target price of $81.14.

Akero Therapeutics Trading Down 3.3%

Akero Therapeutics stock traded down $1.47 during mid-day trading on Monday, hitting $43.46. 1,309,138 shares of the company's stock were exchanged, compared to its average volume of 886,647. The firm has a market capitalization of $3.48 billion, a P/E ratio of -21.73 and a beta of -0.24. Akero Therapeutics has a fifty-two week low of $21.34 and a fifty-two week high of $58.40. The company has a quick ratio of 12.66, a current ratio of 12.66 and a debt-to-equity ratio of 0.02. The company's 50 day simple moving average is $48.82 and its 200-day simple moving average is $46.53.

Institutional Investors Weigh In On Akero Therapeutics

Several institutional investors and hedge funds have recently added to or reduced their stakes in AKRO. Hsbc Holdings PLC grew its position in shares of Akero Therapeutics by 8.5% during the 4th quarter. Hsbc Holdings PLC now owns 7,886 shares of the company's stock valued at $220,000 after acquiring an additional 621 shares during the period. Northern Trust Corp grew its position in shares of Akero Therapeutics by 6.1% during the 4th quarter. Northern Trust Corp now owns 620,321 shares of the company's stock valued at $17,257,000 after acquiring an additional 35,737 shares during the period. Ameriprise Financial Inc. bought a new position in shares of Akero Therapeutics during the 4th quarter valued at approximately $422,000. Cubist Systematic Strategies LLC bought a new position in shares of Akero Therapeutics during the 4th quarter valued at approximately $840,000. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its holdings in Akero Therapeutics by 1.6% in the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 41,442 shares of the company's stock worth $1,153,000 after buying an additional 637 shares during the period.

Insider Activity at Akero Therapeutics

In other news, insider Catriona Yale sold 10,000 shares of the company's stock in a transaction dated Monday, June 16th. The shares were sold at an average price of $54.23, for a total transaction of $542,300.00. Following the transaction, the insider owned 92,231 shares in the company, valued at approximately $5,001,687.13. This represents a 9.78% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jonathan Young sold 12,500 shares of the company's stock in a transaction dated Tuesday, August 12th. The shares were sold at an average price of $47.79, for a total transaction of $597,375.00. Following the transaction, the chief operating officer owned 197,484 shares in the company, valued at $9,437,760.36. This represents a 5.95% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 194,945 shares of company stock worth $9,517,250 over the last three months. 7.07% of the stock is currently owned by company insiders.

About Akero Therapeutics

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.